TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: AUC(0-24h) of darapladib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of darapladib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of cerebrospinal and inflammatory biochemical markers in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of molar incisor hypomineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Serum CEA, TSH, T3, free T4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EKG results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CT or MRI scans of evaluable/measurable lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: T cell regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: remission of generalized anxiety disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Transvalvular gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to atrial fibrillation diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Long-Term Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Success of Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of recovery of T4/T1 of train of four monitoring at 100% of initial value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve from Time Zero to Time of Last Quantifiable Concentration (AUC[0-T])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-Life (T-HALF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Body Clearance (CLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression severity scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients with one or more symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median absolute change in aspartate transaminase (AST) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Median absolute change in alanine aminotransferase (ALT) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of participants who achieve primary fascial closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity and Specificity of DSM-5 Criteria for ASD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival to 36 weeks gestational age free of moderate-severe bronchopulmonary dysplasia
Endpoint domain: Mortality/survival
Primary endpoint: feasibility of Contrast Enhanced Ultrasound (CEUS) in the assessment of Crohn's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 99mTc-rhAnnexin V-128 Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 99mTc-rhAnnexin V-128 Uptake Adjudication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Attenuation Plaque Volume (LAPV) coronary
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low Attenuation Plaque Volume (LAPV) aortic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prolonged hospitalization due to heart failure (> 96 hours)
Endpoint domain: Mortality/survival
Primary endpoint: Use of inotropic - vasopressor therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Use of mechanical circulation support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Cognitive Function Using Trails B
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in Behavioral/Emotional Regulation Using the Behavior Regulation Index From BRIEF
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Tanner Staging Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Steps Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Sedentary Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in WOMAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in number of subjects presenting PPES grade 2/3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Prothrombin Time Results Within the Therapeutic Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bactericidal effect on the causative bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Blood and CSF AUC/MIC relationship
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients without cancer
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity and specificity of BDG for candidemia diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal Incontinence Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pulmonary index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent Change in Total Bleed Episodes Per Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adaptive response to living kidney donation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GU toxicity rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Endoscopic Grading of Nasal Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in rest muscle electrical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle protein synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Incontinent Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Health-Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: change in degree of pain from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in function from baseline
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Device Wear Time and Compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to Provide Timely Arrythmia Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Documentation of Clinically Actionable Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Drug and Alcohol Use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Gambling Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Patient-nurse inter-rater reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR20 Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in abnormal breath test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes from baseline in electrocardiogram (EKG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from baseline in physical exams
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in lab tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in and normalization of BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients evaluated for myocardial viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in proportion of breathalyzer measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No Surgical Re-intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Pictorial Blood Loss Assessment Chart (PBLAC) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in functional resting state brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean change from baseline in level of creativity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean change from baseline in quality of life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical phenotype correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood level profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of AP09004
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Craving based on AUDIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Craving based on MACS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under Curve (AUC) of carboplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of feeding intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence of serious complications
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Percent Change From Baseline in Intact Parathyroid Hormone Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Identification of novel biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in follicular growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of knowledge regarding COVID-19 information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in neck and arm pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Neck Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of patients with complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI change (kg/m^2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients progressing to severe or critical condition
Endpoint domain: Mortality/survival
Primary endpoint: World Health Organization Quality of Life Measure (Brief)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean morphometric diffusion capacity for oxygen (MMDC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in bDMARDS adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in knowledge about bDMARDs management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in mean Hemoglobin A1C (HbA1c) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Distance from Ideal to Center of GTC Frame and BrainLab Thermoplastic Mask
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: metastasis free survival time
Endpoint domain: Mortality/survival
Primary endpoint: Atrial Fibrillation Termination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum netrin-1 value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating Activin A level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin 11β-HSD1 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Anteroposterior ventilation distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Right-to-left ventilation distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: prevention of bereavement and depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Geometric Mean Titer (GMT) at Day 43
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Haemagglutination Inhibition (HI) Titer ≥ 1:40 at Day 43
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Solicited Local, Solicited Systemic, and Other Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: performance of mpMRI as a diagnostic tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Olaparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of ultra-high risk mental health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recidivism
Endpoint domain: Mortality/survival
Primary endpoint: Solicited local and systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence, severity, and relatedness to vaccination of unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence, severity, and relatedness to vaccination of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with clinically significant abnormal safety laboratory findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of participants with clinically significant physical examination and vital signs findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean GSH concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Antimicrobial Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cognitive/Attention Symbol-Digit Modality Test (SDMT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Motor task: transferring of beans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BDNF methylation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: episodic memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: selective attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Composite endpoint of cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: 30% decline in PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absence of detectable HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Quiescin Sulfhydryl Oxidase 1 (QSOX1) levels in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor downstaging ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response rate at Day 21
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood ratio diagnostic criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Duration of Action of Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Therapies Applied
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Measurement of urinary oxalate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: occurrence of postoperative delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to exercise protocol
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in ST-segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in ambulatory blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the whole blood and plasma concentration versus time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak whole blood and plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (T 1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: total cerebral white matter hyperintensity volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG indices during anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Large-for-gestational-age (LGA) occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Gestational Diabetes Mellitus (GDM) occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in depression and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Total Nasal Symptoms Score (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects failing to contact the clinic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Degree of Toxicity of Bevacizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Jaw Opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With GVHD Who Are Tolerable to Tocilizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients who complete the 4 cycles of GV within 15 weeks
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of discontinuations due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of inflammatory and regulatory eosinophils in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inter-observer disagreement at admission lung ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inter-observer disagreement at follow-up lung ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absorption rate of oral Fe-supplements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Extracellular acidification rate (ECAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen consumption rate (OCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Time to Progression
Endpoint domain: Mortality/survival
Primary endpoint: 1-year Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: myocardial angiogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Volume Voided Per Micturition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Diagnosis of portal hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peritoneal membrane function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score measured by EVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with a prescription fill of ribociclib, palbociclib, or abemaciclib
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Post operative pancreatic fistula (POPF)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ADAS-Cog 11 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Homework compliance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Patient tolerability of assigned dose and duration
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Clinical Cure at Test of Cure (TOC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Microbiologic Eradication at TOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Improvement of Individually Measured Signs of the Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes